For patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC), the combination of enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) (EV+P) continued to ...
A new review was published in Volume 16 of Oncotarget on June 17, 2025, titled "Optimizing enfortumab vedotin plus pembrolizumab therapy." First authors Elias Antoine Karam of the Gustave Roussy and ...
In metastatic urothelial carcinoma, Padcev plus Keytruda elicited responses in the first-line setting, with Padcev showing benefit in later lines. Among patients with metastatic urothelial carcinoma — ...
As September concludes, the landscape of GU oncology continues to evolve, with important developments in prostate, bladder, ...
This week’s loving giving local donation goes to an organization that helps women and men in the fight against cancer. It all started with Paula’s story and now it’s Paula’s promise. When Paula ...
Neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy with pelvic lymph node dissection has been the standard of care for muscle-invasive bladder cancer for decades. The advent of ...
CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback